FDA Clears Tecentriq + Lurbinectedin for First-Line Maintenance in Small Cell Lung Cancer

FDA Approves Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer In a landmark decision for the lung cancer community, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S.…

Read MoreFDA Clears Tecentriq + Lurbinectedin for First-Line Maintenance in Small Cell Lung Cancer

Carenet Health Recognized as Major Contender in 2025 Everest Group Care Management PEAK Matrix®

Carenet Health Recognized as Major Contender in Everest Group’s 2025 PEAK Matrix® for Clinical and Care Management Operations Platforms Carenet Health has been formally recognized as a Major Contender in the 2025 PEAK Matrix® Assessment conducted by Everest Group for…

Read MoreCarenet Health Recognized as Major Contender in 2025 Everest Group Care Management PEAK Matrix®

$1M Stephenson Prize Awarded to Dr. Frank McCormick for Pancreatic Cancer Research

Dr. Frank McCormick Receives Inaugural $1 Million Stephenson Global Prize for Pancreatic Cancer Research In a landmark moment for the global cancer research community, Dr. Frank McCormick has been awarded the inaugural Stephenson Global Prize, recognizing his groundbreaking contributions to…

Read More$1M Stephenson Prize Awarded to Dr. Frank McCormick for Pancreatic Cancer Research
Sarepta

Alpha Cognition Inc. Announces $35 Million Oversubscribed Public Offering of Common Shares

Alpha Cognition Inc, a commercial‑stage biopharmaceutical enterprise committed to advancing therapies for neurodegenerative diseases, today announced the successful pricing of an oversubscribed underwritten public offering of its common shares. Under the terms of the offering, the Company is issuing 5,600,000…

Read MoreAlpha Cognition Inc. Announces $35 Million Oversubscribed Public Offering of Common Shares